This article is behind a pay wall...I just copied
Post# of 36537
(Total Views: 444)
Posted On: 09/28/2020 11:04:50 PM
This article is behind a pay wall...I just copied and pasted relevant section.
Thanks!
https://www.bizjournals.com/southflorida/news...-2020.html
The Big Number
$33 million
Amount that Miramar-based Generex Biotechnology Corp. aims to raise on the Nasdaq in a Series A preferred stock offering. The funding would provide it with working capital and “other general corporate purposes,” including paying dividends on the public stock offering and share repurchases, according to a U.S. Securities and Exchange Commission filing.
Currently listed on the Pink Sheets, Generex would offer 1 million shares starting at $33 each if it is approved to be listed on the Nasdaq under the symbol “GNBTP.”
Generex is banking on its majority-owned subsidiary’s vaccine platform to develop and widely distribute a vaccine for the coronavirus.
The company owns NuGenerex Immune-Oncology. Research on NuGenerex’s Ii-Key peptide vaccine technology showed promising results in SARS and breast cancer patients. The company says the technology can be applied to the coronavirus.
Thanks!
https://www.bizjournals.com/southflorida/news...-2020.html
The Big Number
$33 million
Amount that Miramar-based Generex Biotechnology Corp. aims to raise on the Nasdaq in a Series A preferred stock offering. The funding would provide it with working capital and “other general corporate purposes,” including paying dividends on the public stock offering and share repurchases, according to a U.S. Securities and Exchange Commission filing.
Currently listed on the Pink Sheets, Generex would offer 1 million shares starting at $33 each if it is approved to be listed on the Nasdaq under the symbol “GNBTP.”
Generex is banking on its majority-owned subsidiary’s vaccine platform to develop and widely distribute a vaccine for the coronavirus.
The company owns NuGenerex Immune-Oncology. Research on NuGenerex’s Ii-Key peptide vaccine technology showed promising results in SARS and breast cancer patients. The company says the technology can be applied to the coronavirus.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼